$RVVTF announced that it has initiated the develop
Post# of 25580
(Total Views: 184)
Posted On: 08/25/2023 7:56:23 AM
$RVVTF announced that it has initiated the development of a next generation formulation of Bucillamine for the potential treatment of public health medical emergencies including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. In addition, the Company may explore the use of the novel Bucillamine formulation as a potent antioxidant and anti-inflammatory treatment for orphan indications in rare inflammatory disorders such as ischemia-reperfusion injury resulting from solid organ transplantation.
The Company has entered into a sponsored research agreement with the University of Waterloo to develop a novel lyophilized Bucillamine injectable formulation for public health medical emergencies and rare inflammatory disorders. The research program will be conducted at the Wettig Research Group and led by Dr. Shawn Wettig, Ph.D., Principle Investigator, Professor, Assistant Vice President for Graduate Studies at the University of Waterloo. Dr. Wettig's research interests involve aspects of physical chemistry, solution thermodynamics, biochemistry and cell biology applied to the study of self-assembling systems. A key aspect of Dr. Wettig’s research is the design of novel surface-active compounds that, in addition to providing the desired characteristics of self-assembly and control of particle dimensions on the nanometer size scale, can also provide enhanced pharmaceutical applications such as targeted delivery and/or enhanced bio-distribution of an active compound. Dr. Wettig obtained his Ph.D. studying the physical chemistry of novel mixed surfactant/polymer systems with Dr. Ron Verrall in the Department of Chemistry at the University of Saskatchewan. He was appointed Associate Dean of Science for Graduate Studies in October 2018.
https://finance.yahoo.com/news/revive-therape...00575.html
The Company has entered into a sponsored research agreement with the University of Waterloo to develop a novel lyophilized Bucillamine injectable formulation for public health medical emergencies and rare inflammatory disorders. The research program will be conducted at the Wettig Research Group and led by Dr. Shawn Wettig, Ph.D., Principle Investigator, Professor, Assistant Vice President for Graduate Studies at the University of Waterloo. Dr. Wettig's research interests involve aspects of physical chemistry, solution thermodynamics, biochemistry and cell biology applied to the study of self-assembling systems. A key aspect of Dr. Wettig’s research is the design of novel surface-active compounds that, in addition to providing the desired characteristics of self-assembly and control of particle dimensions on the nanometer size scale, can also provide enhanced pharmaceutical applications such as targeted delivery and/or enhanced bio-distribution of an active compound. Dr. Wettig obtained his Ph.D. studying the physical chemistry of novel mixed surfactant/polymer systems with Dr. Ron Verrall in the Department of Chemistry at the University of Saskatchewan. He was appointed Associate Dean of Science for Graduate Studies in October 2018.
https://finance.yahoo.com/news/revive-therape...00575.html
(0)
(0)